Some patients reach their goals within 6-9 months, while others continue treatment longer
Patients may receive weekly or bi-weekly injections, but this can be adjusted based on your response and goals
Cosden M, Jinn S, Yao L et al (2021) A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
Melanocytic atypia is not a typical feature and, if present, particularly when accompanied by a pagetoid spread of melanocytes, should raise concern for a significant precursor lesion or even melanoma in situ
For both trials, a lack of effect was concluded if the 90% CI for the ratio of the AUC 0-24,SS (Trial 1) or AUC 0- , (Trial 2) with/without oral semaglutide was within the pre-specified interval of 0.801.25
For type 2 diabetes management , NICE guidance (NG28) recommends GLP-1 agonists as second- or third-line therapy when metformin and other oral agents provide inadequate glycaemic control, or as an alternative to insulin in appropriate patients